Search research articles
Contact Us
Filters
Showing results (241-250 of 328) with videos related to
Page
of 33
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 5, 2024
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
Alexander H R Varey, Isabel Li, Mary-Ann El Sharouni, et al.
Journal for Immunotherapy of Cancer
|
October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.
Science Advances
|
April 29, 2022
Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy
Thomas S C Ng, Huiyu Hu, Stefan Kronister, et al.
Nature Immunology
|
July 31, 2019
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistance
Vivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.
Nature Immunology
|
September 26, 2019
Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistance
Vivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
Eleanor E Handel, Janet McKeown, Joe Wei, et al.
Journal for Immunotherapy of Cancer
|
April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
The New England Journal of Medicine
|
September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
Cancer Immunology Research
|
September 28, 2016
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Douglas B Johnson, Garrett M Frampton, Matthew J Rioth, et al.
Cancer Discovery
|
November 23, 2013
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition
Nikhil Wagle, Eliezer M Van Allen, Daniel J Treacy, et al.
Page
of 33
Search research articles
Search
Showing results (241-250 of 328) with videos related to
Sort By:
Page
of 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 5, 2024
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
Alexander H R Varey, Isabel Li, Mary-Ann El Sharouni, et al.
Journal for Immunotherapy of Cancer
|
October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.
Science Advances
|
April 29, 2022
Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy
Thomas S C Ng, Huiyu Hu, Stefan Kronister, et al.
Nature Immunology
|
July 31, 2019
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistance
Vivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.
Nature Immunology
|
September 26, 2019
Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistance
Vivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
Eleanor E Handel, Janet McKeown, Joe Wei, et al.
Journal for Immunotherapy of Cancer
|
April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
The New England Journal of Medicine
|
September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
Cancer Immunology Research
|
September 28, 2016
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Douglas B Johnson, Garrett M Frampton, Matthew J Rioth, et al.
Cancer Discovery
|
November 23, 2013
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition
Nikhil Wagle, Eliezer M Van Allen, Daniel J Treacy, et al.
Page
of 33